Mexiletine, capsule, 150mg, PO BID, 14 days

A total of 23 subjects were enrolled. 11 were randomized to receive study drug first, followed by placebo. 12 subjects received placebo first and study drug second. Overall participant characteristics are displayed in the baseline table.

Total Subjects Enrolled

Age, Customized

Sex/Gender, Customized

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

The average of the daily recording of number of muscle cramps that occurred in the last 24 hours- over a 6 week period.

Mexiletine, capsule, 150mg, PO BID, 14 days
Placebo, capsule, PO BID, 14 days

Mexiletine First/Placebo Second

Placebo, capsule, PO BID, 14 days
Mexiletine, capsule, 150mg, PO BID, 14 days

Placebo First/Mexiletine Second

Daily Muscle Cramps

Daily cramp severity was rated on the 100-unit visual analog scale. Scores ranged from 0 to 100, with 100 being the greatest amount of cramp severity

Mexiletine, capsule, 150mg, PO BID, 14 days
Mexiletine: Sodium channel blocker

Mexiletine First

Placebo, capsule, PO BID, 14 days
Placebo: Placebo

Placebo First

Cramp Severity

First Dose

Washout

Second Dose

Dr. Bjorn Oskarsson

Mexiletine

Placebo

Muscle Cramps in Amyotrophic Lateral Sclerosis

UCD Telehealth Network - Lake Almanor Clinic

UCSD Department of Neurosciences ALS Clinical Trials (ACT) Program

UCLA Neuromuscular Research Program

UCD Telehealth Network

UC Irvine Health ALS & Neuromuscular Center

UC, Davis Medical Center ALS Clinic

Mexiletine for the Treatment of Muscle Cramps in ALS

Bjorn Oskarsson, MD

Assistant Professor of Clinical Neurology

University of California, Davis

ALS Association

machado-joseph disease

nausea

machado-joseph disease/nausea

Mexiletine for the Treatment of Muscle Cramps in ALS

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası